Herpes ZosterNCT01772160
Study to Estimate the Burden of Herpes Zoster (HZ) and Post-herpetic Neuralgia (PHN) in Italy
An observational study of Herpes Zoster and Herpes Zoster Vaccine, run by GlaxoSmithKline at 43 sites in Italy.
Trial summary
The purpose of this study is to collect data on the incidence, complications, economic burden and impact on the quality of life in adults aged ≥ 50 years with HZ disease in Italy. Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Herpes Zoster, Herpes Zoster Vaccine
- What is being tested?
- Data collection
- How many people
- 395 participants
- Where
- 43 sitesItaly
- Study dates
- 26 Feb 2013to 5 Oct 2016
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult population, male or female aged ≥ 50 years of age presenting with a HZ episode.
Who may be able to join
- A male or female ≥ 50 years of age at the time of study enrolment presenting with acute HZ.
- HZ diagnosis for this HZ episode:
- Is his/her first outpatient diagnosis (i.e. initial consultation), OR
- Took place at another site/centre (e.g. emergency room or Dermatologist/Specialist practice) provided the HZ diagnosis is not more than 7 days before the initial visit for the present study (i.e. secondary consultation).
- Written informed consent obtained from the patient.
- Ability to comply with study procedures.
Who cannot join
- Patient participating in another clinical study (participation in another observational, non-interventional trial is allowed).
Trial locations and contacts
43 sites in 1 country.
43 sites in 1 country
Italy43 sites
GSK Investigational Site
Alessandria, Piedmont, 15121
GSK Investigational Site
Alessano (LE)
GSK Investigational Site
Angera (VA), Lombardy
GSK Investigational Site
Arcidosso (GR), Tuscany, 58031
GSK Investigational Site
Arcisate (VA), Lombardy, 21051
GSK Investigational Site
Arezzo, Tuscany, 52100
GSK Investigational Site
Cavallino (LE), Apulia, 73020
GSK Investigational Site
Civitella Paganico (GR), Tuscany, 58045
GSK Investigational Site
Comerio (VA), Lombardy, 21020
GSK Investigational Site
Copertino (LE), Apulia, 73043
GSK Investigational Site
Cutrofiano (LE), Apulia, 73020
GSK Investigational Site
Fagnano Olona (VA), Lombardy, 21054
GSK Investigational Site
Follonica (GR), Tuscany, 58022
GSK Investigational Site
Frugarolo (AL), Piedmont, 15065
GSK Investigational Site
Galatina (LE), Apulia, 73013
GSK Investigational Site
Ghirla Valganna (VA), Lombardy, 21030
GSK Investigational Site
Grosseto, Tuscany, 58100
GSK Investigational Site
Induno Olona (VA), Lombardy, 21040
GSK Investigational Site
Lucignano (AR), Tuscany, 52046
GSK Investigational Site
Montesano S. (LE), Apulia, 73035
GSK Investigational Site
Naples, Campania, 80125
GSK Investigational Site
Naples, Campania, 80126
GSK Investigational Site
Orbetello (GR), Tuscany, 58015
GSK Investigational Site
Oviglio (AL), Piedmont, 15026
GSK Investigational Site
Parabita (LE), Apulia, 73052
GSK Investigational Site
Perugia, Umbria, 06125
GSK Investigational Site
Perugia, Umbria, 06126
GSK Investigational Site
Perugia, Umbria
GSK Investigational Site
Ripa (PG), Umbria, 06134
GSK Investigational Site
Rome, Lazio, 00141
GSK Investigational Site
Rome, Lazio, 00142
GSK Investigational Site
Rome, Lazio, 00144
GSK Investigational Site
Rome, Lazio, 00162
GSK Investigational Site
Rome, Lazio, 00176
GSK Investigational Site
Rome, Lazio, 00197
GSK Investigational Site
Rome, 00144
GSK Investigational Site
Sale (AL), Piedmont, 15045
GSK Investigational Site
Sassofortino (GR), Tuscany, 58029
GSK Investigational Site
Sesto Calende (VA), Lombardy, 21018
GSK Investigational Site
Solbiate Olona (VA), Lombardy, 21052
GSK Investigational Site
Specchia (LE), Apulia, 73040
GSK Investigational Site
Varese, Lombardy, 21100
GSK Investigational Site
Villalvernia (AL), Piedmont, 15050
About this study
Official title: Population Based Surveillance to Estimate the Burden of Herpes Zoster and Post-herpetic Neuralgia in Italy
The purpose of this study is to collect data on the incidence, complications, economic burden and impact on the quality of life in adults aged ≥ 50 years with HZ disease in Italy.
Read the detailed description
The surveillance/recruitment period will take approximately 2 years and once the enrolment of HZ patients has ended, the study will continue for a maximum of 9 months to allow for completion of the follow-up of potential PHN cases.
The data will be captured at protocol specified time-points based on the time of enrolment of each subject.
- Conditions
- Herpes Zoster, Herpes Zoster Vaccine
- Being tested
- Data collection
- Keywords
- Adults, Italy, Herpes Zoster, Complications, Quality of life, Surveillance, Burden, Cost, Incidence
- Medical subject headings
- Herpes Zoster
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Data collectionOther
HZ/PHN booklet, HZ/PHN file and logbook. HZ/PHN booklet will be completed by the patient and the HZ/PHN file and logbook will be completed by the participating general practitioner.
| Study group | Role | What they receive |
|---|---|---|
| Herpes Zoster Group | Male or female subjects aged 50 years or above, presenting with a herpes zoster (HZ) episode. Receives: Other: Data collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Incidence Rate of Herpes Zoster (HZ) Cases, by Age and Gender
A case of HZ was defined as new unilateral pain (broadly defined to include allodynia and pruritus) accompanied by unilateral rash and no alternative diagnosis. Age ranges were 50-54, 55-59, 60-64, 65-69, 70-74, 75-79 and greater than or equal to (≥) 80 years. The incidence rate was expressed as the number of HZ cases per (/) 1000 person-years.
Measured: Day 0 to 2 years
Secondary outcomes (16)
Percentage of Postherpetic Neuralgia (PHN) Cases Among HZ, Overall
PHN persistence refers to pain occurring or persisting from Day 90 to Day 270 after the rash onset. PHN was assessed via the Zoster Pain Inventory (ZBPI) questionnaire, which includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'.
Measured: At Day 90, 180 and 270 after onset of HZ
General Medical History of Cases With HZ, Overall
General medical history focused on characteristics such as patient pre-existing condition and diseases (local trauma, diabetes mellitus, liver disease, alcoholism, renal failure/dialysis, emotional problems, stress or depression, blood malignancy, solid malignancy, hematopoetic cell/ bone marrow transplant, solid organ transplantation, HIV infection, hepatitis C under active therapy, autoimmune disease active and under therapy, other).
Measured: Between Day 0 and Day 270.
Other General Medical History Characteristics for HZ Cases, Overall
Other general medical history characteristics referred to arterial problems, cerebral problems, gastric problems, gastric problems, prostate problems (arterial hypertension and allergic rhinitis, arterial hypertension and pacemaker, arteriopathy and past nun-Hodgkin lymphoma, atrial fibrillation, bronchopathy, cerebral thrombosis, cholecyst, chronic cerebral ischemia, chronic leukemia, chronic obstructive pulmonary disease, epilepsy, gastric lymphoma, gastropathy, hypertension, hypertension and hypothyroidism after surgery, hypertension dyslipidemia and hyperthyroidism, hypothyroidism hypertension, polycythaemia, polycythaemia from 10 years, prostate neoplasm, prostate oral anticoagulant therapy cardiopathy, prostatic cancer, right feet arthralgia, thrombocytopenia, vasculopathy chronic brain).
Measured: Between Day 0 and Day 270.
Clinical Information of Cases With HZ, Overall
Clinical information of HZ cases referred to experience of any symptoms before rash, actual symptoms before rash (SBR), any complications at initial visit.
Measured: Between Day 0 and Day 270
Complications Related to HZ Cases, Overall
HZ related complications refer to cutaneous complications (Varicella Zoster Virus [VZV] dissemination, Bacterial superinfection), ocular (Loss of corneal sensation, Keratitis, Scleritis, Uveitis, Iridocyclitis), neurological (Meningo-encephalitis, Cranial nerve palsies, Peripheral nerve palsies, Ramsay-Hunt syndrome, Persistent HZ-related Pain), visceral [Neural extension of VZV infection (bronchitis, esophagitis,cystitis), VZV dissemination (pneumonia, arthritis, hepatitis] and other.
Measured: Between Day 0 and Day 270
Other Complications Related to HZ Cases, Overall
HZ related other complications refer to axillary lympagenopathy, burning sensation, hypoacusis, itching and rectum pain.
Measured: Between Day 0 and Day 270
Direct Medical Costs, Direct Non-medical Costs and Indirect Costs
Cost data related to HZ included medication, procedures and referral to hospital/specialist for direct medical costs, transport for direct non-medical costs and missed time from work, sick certificate for the indirect costs.
Measured: Up to Day 90
Worst Pain Assessment in HZ Subjects
The ZBPI is an assessment tool in the form of a questionnaire completed by the patient that is specifically designed to assess HZ-associated pain and discomfort. the ZBPI includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'. Note: The Day 90 window included assessments between Day 83 and Day 97 relative to day of rash onset.
Measured: At Day 90
Average Pain Assessment in HZ Subjects
The ZBPI is an assessment tool in the form of a questionnaire completed by the patient that is specifically designed to assess HZ-associated pain and discomfort. the ZBPI includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'. Note: The Day 90 window included assessments between Day 83 and Day 97 relative to day of rash onset.
Measured: At Day 90
Impact of HZ on Quality of Life as Assessed by the Zoster Pain Inventory
PHN persistence refers to pain occurring or persisting between 90-270 days after the rash onset. PHN was assessed via the Zoster Pain Inventory (ZBPI) questionnaire, which includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'.
Measured: At Day 0, 15, 30, 60, 90
Impact of HZ on Quality of Life as Assessed by the EuroQoL-Five Digits
EuroQoL-Five Digits (EQ-5D) is a standardised instrument for use as a measure of health outcome and is designed for self-completion by respondents. Its current format is 3-level and 5 dimensional (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The EQ-5D index was derived from the ratings recorded every 3 months for each of the five individual items (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The EQ-5D index/scale goes from 0 (worst health state) to 1 (perfect health state).
Measured: At Day 0, 15, 30, 60, 90
PHN Direct Medical Costs, Direct Non-medical Costs and Indirect Costs by Payer/Societal Perspective
Cost data related to HZ included medication, procedures and referral to hospital/specialist for direct medical costs, transport for direct non-medical costs and missed time from work, sick certificate for the indirect costs.
Measured: Between Day 90 and Day 270
Worst Pain Assessment in PHN Subjects
The ZBPI is an assessment tool in the form of a questionnaire completed by the patient that is specifically designed to assess HZ-associated pain and discomfort. the ZBPI includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'. Note: The Day 90 window included assessments between Day 83 and Day 97 relative to day of rash onset.
Measured: At Day 90
Average Pain Assessment in PHN Subjects
The ZBPI is an assessment tool in the form of a questionnaire completed by the patient that is specifically designed to assess HZ-associated pain and discomfort. The ZBPI includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'. Note: The Day 90 window included assessments between Day 83 and Day 97 relative to day of rash onset.
Measured: At Day 90
Impact of PHN on Quality of Life as Assessed by the Zoster Pain Inventory
PHN persistence refers to pain occurring or persisting between 90-270 days after the rash onset. PHN was assessed via the Zoster Pain Inventory (ZBPI) questionnaire, which includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'.
Measured: At Day 0, 15, 30, 60, 90
Impact of PHN on Quality of Life as Assessed by the EuroQoL-Five Digits
EuroQoL-Five Digits (EQ-5D) is a standardised instrument for use as a measure of health outcome and is designed for self-completion by respondents. Its current format is 3-level and 5 dimensional (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The EQ-5D index was derived from the ratings recorded every 3 months for each of the five individual items (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The EQ-5D index was 0 (worst health state) to 1 (best health state).
Measured: At Day 0, 15, 30, 60, 90
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Jan 2013 (estimated)
- Study start26 Feb 2013
- Primary completion5 Oct 2016
- Study completion5 Oct 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Herpes ZosterStudies of the same condition, open and under way.
- More trials run by GlaxoSmithKlineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 395 participants (actual)
Sponsor and investigators
- Lead sponsor
- GlaxoSmithKline
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- GSK Clinical Trials, Study director, GlaxoSmithKline
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01772160
- Sponsor's protocol ID
- 116208
- Status last verified
- May 2020
- First submitted
- 17 Jan 2013
- Last updated
- 22 May 2020
- Results posted
- Yes, on ClinicalTrials.gov
- Individual data sharing
- Yes: IPD for this study will be made available via the Clinical Study Data Request site.
Publications
Salvetti A, Ferrari V, Garofalo R, Gazzaniga P, Guerroni A, Metrucci A, Sessa A, Severi ML, Nati G, Ruggeri M, Rossi A, Cappellari L, Gopala K, Tosatto R, Simone B. Incidence of herpes zoster and postherpetic neuralgia in Italian adults aged >/=50 years: A prospective study. Prev Med Rep. 2019 Apr 24;14:100882. doi: 10.1016/j.pmedr.2019.100882. eCollection 2019 Jun.
PubMed 31193254Matthews S, De Maria A, Passamonti M, Ristori G, Loiacono I, Puggina A, Curran D. The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy. Open Forum Infect Dis. 2019 Jan 12;6(2):ofz007. doi: 10.1093/ofid/ofz007. eCollection 2019 Feb.
PubMed 30793003
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Population Based Surveillance to Estimate the Burden of Herpes Zoster and Post-herpetic Neuralgia in Italy
- ClinicalTrials.gov ID
- NCT01772160
- Acronym / sponsor ID
- 116208
- Conditions
- Herpes Zoster, Herpes Zoster Vaccine
- Keywords
- Adults, Italy, Herpes Zoster, Complications, Quality of life, Surveillance, Burden, Cost
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 395 participants (actual)
- Lead sponsor
- GlaxoSmithKlineIndustry (pharma, biotech, devices)
- Study start
- 26 Feb 2013 (actual)
- Primary completion
- 5 Oct 2016 (actual)
- Study completion
- 5 Oct 2016 (actual)
- First posted
- 21 Jan 2013 (estimated)
- Results
- Posted 22 May 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to collect data on the incidence, complications, economic burden and impact on the quality of life in adults aged ≥ 50 years with HZ disease in Italy.
Detailed description
The surveillance/recruitment period will take approximately 2 years and once the enrolment of HZ patients has ended, the study will continue for a maximum of 9 months to allow for completion of the follow-up of potential PHN cases.
The data will be captured at protocol specified time-points based on the time of enrolment of each subject.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Herpes Zoster Group | – | Other: Data collectionMale or female subjects aged 50 years or above, presenting with a herpes zoster (HZ) episode. |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult population, male or female aged ≥ 50 years of age presenting with a HZ episode.
Key inclusion criteria (6 listed)
- A male or female ≥ 50 years of age at the time of study enrolment presenting with acute HZ.
- HZ diagnosis for this HZ episode:
- Written informed consent obtained from the patient.
- Ability to comply with study procedures.
Key exclusion criteria (1 listed)
- Patient participating in another clinical study (participation in another observational, non-interventional trial is allowed).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Data collectionHZ/PHN booklet, HZ/PHN file and logbook. HZ/PHN booklet will be completed by the patient and the HZ/PHN file and logbook will be completed by the participating general practitioner. | Other | Herpes Zoster Group |
Primary outcome
Overall Incidence Rate of Herpes Zoster (HZ) Cases, by Age and Gender
Time frame: Day 0 to 2 years
A case of HZ was defined as new unilateral pain (broadly defined to include allodynia and pruritus) accompanied by unilateral rash and no alternative diagnosis. Age ranges were 50-54, 55-59, 60-64, 65-69, 70-74, 75-79 and greater than or equal to (≥) 80 years. The incidence rate was expressed as the number of HZ cases per (/) 1000 person-years.
16 secondary outcomes
Percentage of Postherpetic Neuralgia (PHN) Cases Among HZ, Overall
Time frame: At Day 90, 180 and 270 after onset of HZ
General Medical History of Cases With HZ, Overall
Time frame: Between Day 0 and Day 270.
Other General Medical History Characteristics for HZ Cases, Overall
Time frame: Between Day 0 and Day 270.
Clinical Information of Cases With HZ, Overall
Time frame: Between Day 0 and Day 270
Complications Related to HZ Cases, Overall
Time frame: Between Day 0 and Day 270
Other Complications Related to HZ Cases, Overall
Time frame: Between Day 0 and Day 270
Direct Medical Costs, Direct Non-medical Costs and Indirect Costs
Time frame: Up to Day 90
Worst Pain Assessment in HZ Subjects
Time frame: At Day 90
Average Pain Assessment in HZ Subjects
Time frame: At Day 90
Impact of HZ on Quality of Life as Assessed by the Zoster Pain Inventory
Time frame: At Day 0, 15, 30, 60, 90
Impact of HZ on Quality of Life as Assessed by the EuroQoL-Five Digits
Time frame: At Day 0, 15, 30, 60, 90
PHN Direct Medical Costs, Direct Non-medical Costs and Indirect Costs by Payer/Societal Perspective
Time frame: Between Day 90 and Day 270
Worst Pain Assessment in PHN Subjects
Time frame: At Day 90
Average Pain Assessment in PHN Subjects
Time frame: At Day 90
Impact of PHN on Quality of Life as Assessed by the Zoster Pain Inventory
Time frame: At Day 0, 15, 30, 60, 90
Impact of PHN on Quality of Life as Assessed by the EuroQoL-Five Digits
Time frame: At Day 0, 15, 30, 60, 90
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2020.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 31193254Salvetti A, Ferrari V, Garofalo R, Gazzaniga P, Guerroni A, Metrucci A, Sessa A, Severi ML, Nati G, Ruggeri M, Rossi A, Cappellari L, Gopala K, Tosatto R, Simone B. Incidence of herpes zoster and postherpetic neuralgia in Italian adults aged >/=50 years: A prospective study. Prev Med Rep. 2019 Apr 24;14:100882. doi: 10.1016/j.pmedr.2019.100882. eCollection 2019 Jun.
- Derived from this study: PubMed 30793003Matthews S, De Maria A, Passamonti M, Ristori G, Loiacono I, Puggina A, Curran D. The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy. Open Forum Infect Dis. 2019 Jan 12;6(2):ofz007. doi: 10.1093/ofid/ofz007. eCollection 2019 Feb.
- Individual participant dataSharing planned: Yes. IPD for this study will be made available via the Clinical Study Data Request site.
Related trials for Herpes Zoster
RecruitingPhase 1/2
Clinical Trial of Recombinant Herpes Zoster Vaccine (ZFA01 Adjuvant, CHO Cells)
Herpes Zoster
Active, not recruitingPhase 2
A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
Herpes Zoster (HZ), Infectious Diseases
RecruitingPhase 1/2
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
Herpes Zoster
RecruitingPhase 4
Safety of the Herpes Zoster Subunit Vaccine in Lupus
Systemic Lupus Erythematosus
Active, not recruitingPhase 1/2
Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older
Herpes Zoster, Herpes Zoster Vaccine
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
GSK Clinical Trials study director
GlaxoSmithKline
43 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Herpes Zoster and Herpes Zoster Vaccine, run by GlaxoSmithKline at 43 sites in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 May 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 43 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 22 May 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Incidence Rate of Herpes Zoster (HZ) Cases, by Age and Gender (time frame: Day 0 to 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01772160, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2020.